- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
A Gray Area for Reimbursement: Medical Foods for Non–Inborn Errors of MetabolismMost non–inborn errors of metabolism (non-IEM) medical foods (MFs) do not meet the regulatory MF definition and lack scientific evidence for safety and efficacy. Non-IEM MFs are not yet ready for reimbursement by public insurers.
Latest:
A Cost-Effectiveness Analysis of Cardiology eConsults for Medicaid PatientsA randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional face-to-face consultations.
Latest:
Community as Part of the Prescription: Social Media in Diabetes CareThis commentary was adapted from an appearance by the authors at Patient-Centered Diabetes Care, a conference jointly presented by The American Journal of Managed Care and Joslin Diabetes Center.
Latest:
Predialysis Nephrology Care Among Older Veterans Using Department of Veterans Affairs or Medicare-Covered ServicesMany older veterans do not receive appropriate nephrology care before beginning dialysis. Dual use of Veterans Affairs and Medicare-covered services was associated with better patterns of care.
Latest:
Impact of an Online Prescription Management Account on Medication AdherenceOnline prescription management accounts may help promote medication adherence, as utilizing patients had a higher proportion of days covered than nonusers.
Latest:
The Incidence and Costs of Hypoglycemia in Type 2 DiabetesThe overall incidence of hypoglycemia was considerable in this large working-age population and was associated with $52 million (2008 dollars) in direct medical costs.
Latest:
False Activation of the Cardiac Catheterization Laboratory for Primary PCIBetween 2005 and 2011, rates of cardiac catheterization laboratory false activation doubled while mean door-to-balloon times for primary PCI declined.
Latest:
Cost Analysis Review of Stroke Centers, Telestroke, and rt-PAUse of rt-PA is associated with long-term cost savings, but more high-quality, current cost-effectiveness research is needed for stroke centers, care networks, and telemedicine.
Latest:
A Systematic Review of Measurement Properties of Instruments Assessing PresenteeismA systematic review of presenteeism instruments found that most have been validated to some extent, but evidence for criterion validity is virtually absent.
Latest:
Curtailing Utilization of Low-Value Medical CareWorking together to reduce low-value care, stakeholders can help eliminate wasteful spending and deliver on their goal to improve the health of Americans by delivering higher-quality care at lower cost.
Latest:
Medicare Beneficiaries’ Out-of-Pocket Costs for Commonly Used Generic Drugs, 2009-2017Out-of-pocket costs required by Medicare prescription drug plans for drugs available through Walmart’s generic drug discount program have decreased from 2009 to 2017.
Latest:
Comparison of the Use of Top-Ranked Cancer Hospitals Between Medicare Advantage and Traditional MedicareMedicare Advantage enrollees, particularly those with lower out-of-network benefits, may have restricted access to top-ranked hospitals for complex cancer care compared with traditional Medicare enrollees.
Latest:
Cost-effectiveness Evaluation of a Home Blood Pressure Monitoring ProgramA technology-based, pharmacist-run home blood pressure monitoring program improves health outcomes by investing $20.50 per mm Hg systolic blood pressure lowered and $3300 per life-year gained.
Latest:
Prevalence, Effectiveness, and Characteristics of Pharmacy-Based Medication Synchronization ProgramsThis study evaluates the prevalence, structure, and key features of pharmacy-based programs to synchronize prescription fill dates, about which, little is known.
Latest:
The Impact of Kaua'i Care Transition Intervention on Hospital Readmission RatesBy enrolling selected high-risk elderly patients into the intervention, then empowering and educating them, this study successfully reduced hospital readmission rates.
Latest:
COPD Exacerbation Costs in the IMPACT Study: A Within-Trial AnalysisTreatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
